Literature DB >> 6641123

Serum and urine analysis of the aminoterminal procollagen peptide type III by radioimmunoassay with antibody Fab fragments.

H Rohde, I Langer, T Krieg, R Timpl.   

Abstract

A radioimmunoassay based on antibody Fab fragments was developed for the aminoterminal peptide Col 1-3 of bovine type III procollagen. This assay does not distinguish the intact aminopropeptide Col 1-3 from its globular fragment Col 1. Parallel inhibition profiles were observed with human serum and urine allowing the simultaneous quantitative determination of intact and fragmented antigens in these samples. Most of the material has a size similar to that of fragment Col 1 indicating that the aminopropeptide is degraded under physiologic conditions. The concentration of aminopeptide in normal sera was in the range 15-63 ng/ml. Daily excretion was found to be in the range 30-110 micrograms. More than 50% of patients with alcoholic hepatitis and liver cirrhosis showed elevated serum levels of aminopropeptide by the Fab assay. Elevated concentrations were detected more frequently with an antibody radioimmunoassay which measures mainly the intact form of the aminopropeptide. It is suggested that analysis of patients material by both assays could improve their diagnostic application.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6641123     DOI: 10.1016/s0174-173x(83)80018-1

Source DB:  PubMed          Journal:  Coll Relat Res        ISSN: 0174-173X


  10 in total

1.  Markers of collagen and basement membrane metabolism in sera of patients with progressive systemic sclerosis.

Authors:  N G Guseva; N V Anikina; R Myllylä; L Risteli; J Risteli; J V Chochlova; K I Kivirikko; V A Nassonova
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

2.  Serum levels of type III collagen aminopropeptide in patients with systemic scleroderma.

Authors:  S Majewski; A Skiendzielewska; B Makieła; S Jablońska; M Błaszczyk
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

3.  Serum aminoterminal type III procollagen peptide in inflammatory and degenerative rheumatic disorders.

Authors:  K Hørslev-Petersen; K D Bentsen; P Junker; F K Mathiesen; T M Hansen; I Lorenzen
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

4.  Prolonged exercise causes an increase in the activity of galactosylhydroxylysyl glucosyltransferase and in the concentration of type III procollagen aminopropeptide in human serum.

Authors:  T E Takala; J Vuori; H Anttinen; K Väänänen; R Myllylä
Journal:  Pflugers Arch       Date:  1986-11       Impact factor: 3.657

5.  Evidence for protein oedema, neutrophil influx, and enhanced collagen production in lungs of patients with systemic sclerosis.

Authors:  N K Harrison; R J McAnulty; P L Haslam; C M Black; G J Laurent
Journal:  Thorax       Date:  1990-08       Impact factor: 9.139

6.  Complete amino acid sequence of the N-terminal extension of calf skin type III procollagen.

Authors:  A Brandt; R W Glanville; D Hörlein; P Bruckner; R Timpl; P P Fietzek; K Kühn
Journal:  Biochem J       Date:  1984-04-15       Impact factor: 3.857

7.  Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine.

Authors:  K Hørslev-Petersen; K D Bentsen; A Engström-Laurent; P Junker; P Halberg; I Lorenzen
Journal:  Ann Rheum Dis       Date:  1988-02       Impact factor: 19.103

8.  Transpulmonary gradient of type III procollagen peptides: acute effects of cardio-pulmonary bypass.

Authors:  N K Harrison; G J Laurent; T W Evans
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

9.  The aminoterminal-type-III procollagen peptide and proteoglycans in serum and synovial fluid of patients with rheumatoid arthritis or reactive arthritis.

Authors:  K Hørslev-Petersen; T Saxne; D Haar; B S Thomsen; K D Bentsen; P Junker; I Lorenzen
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

10.  Radioimmunoassay for the carboxy-terminal cross-linking domain of type IV (basement membrane) procollagen in body fluids. Characterization and application to collagen type IV metabolism in fibrotic liver disease.

Authors:  D Schuppan; M Besser; R Schwarting; E G Hahn
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.